Company News: Page (1) of 1 - 04/21/14 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Alliqua Biomedical Announces New Data on sorbion(R) Wound Care Dressings to be Presented at the Spring 2014 SAWC Meeting

(April 21, 2014)

LANGHORNE, Pa., April 21, 2014 (GLOBE NEWSWIRE) -- Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, announces new data from the Company's sorbion® product line will be presented at the Spring 2014 Symposium on Advanced Wound Care to be held at the Gaylord Palms Hotel and Convention Center in Orlando, Florida on April 23-27. Thirteen abstracts will highlight data on cytokine and protease binding capabilities and bacterial sequestration and retention through exudate management by sorbion® dressings. The resulting reduction of inflammation and impact on other factors that affect wound healing will be discussed. 



Separately, the Company will co-sponsor a breakfast symposium with sorbion titled "Cost Savings Through Hydrokinetic Fibers in Acute and Chronic Wounds" on Friday, April 25 from 7:30am-9:00am ET. The symposium will focus on the beneficial attributes of advanced wound care dressings from sorbion using hydrokinetic fibers in acute and chronic wounds. Attendees will learn about the dressing's ability to absorb and hold high quantities of exudate, reduce bioburden through microbial sequestration and use as a way to decrease (or manage) utilization of negative pressure wound therapy, which can result in significant cost savings. The participants will be Keith Cutting, MN (Daresbury, UK), Randall Wolcott, MD (Lubbock, TX), Cornelia Wiegand, PhD (Jena, Germany) and S. Kwon Lee, MD (Sacramento, CA).



David Johnson, CEO of Alliqua, said, "The SAWC meeting is the largest annual gathering of wound care clinicians in the U.S. We are very excited to participate in this program and highlight the specific advantages presented by sorbion's wound care dressings."


Highlights of the Poster Presentations:





  • Determination of the Binding of PMN Elastase and Matrix Metalloproteases by a Non‐traumatic Fiber Dressing in vitro (LB_043)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Comparison of the Fluid Management by NPWT and a Special Hydrokinetic‐fiber Dressing in vitro (LB_036)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • A Hydrokinetic Fiber Dressing Binds TNF‐alpha and IL-1 beta and reduces ROS and RNS in vitro (LB_040)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Reduction of PMN Elastase and Matrix Metalloproteases by a Hydrokinetic Fiber Dressing in vitro (LB_041)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Evaluation of a Hydrokinetic Fiber Dressing and a Hydroactive‐fiber Dressing with Regard to Binding of tnf‐alpha and IL‐1beta and Reduction of ROS and RNS in vitro (LB_037)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Comparison of the Effects of a Hydrokinetic Fiber Dressing and a Hydroactive‐fiber Dressing on PMN Elastase and Matrix Metalloproteases in vitro (LB_038)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Binding of TNF‐alpha and IL‐1beta and reduction of ROS and RNS by a non‐traumatic fiber dressing in vitro (LB_042) 

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Binding of Matrix Metalloproteases by Moisture‐retentive Dressings in vitro (LB_039)

    C. Wiegand, D. Reichmann, A. Maassen, A. Riesinger, U.-C. Hipler


  • Investigating the Potential for Hydration Response Technology (HRT) Wound Dressing to Substitute for Generic Negative Pressure Wound Therapy (NPWT) in a Range of Wound Types ‐ a Delphi Inquiry (IR_011)

    K. F. Cutting


  • A Clinical Evaluation of a Dressing Containing Hydrokinetic Fibres in Ten Venous Leg Ulcer Patients Attending a Complex Wound Clinic (CS_041)

    K. F. Cutting


  • A Clinical Evaluation of a Dressing Containing Hydrokinetic Fibres Designed to be Applied to Wounds That are Difficult to Dress or in Awkward Anatomical Areas (CR_025)

    K. F. Cutting


  • A Retrospective Cost Analysis of NPWT and Hydrokinetic Fiber Dressing for the Management of Serious Wounds (CR_025) 

    M. H. E. Hermans


  • Bacterial Sequestration & Retention Properties of a Hydrokinetic Fiber Dressing and Comparators:Results of a Series of in vitro Experiments

    M.H.E. Hermans, K.F. Cutting



About Alliqua, Inc.



Alliqua is a provider of advanced wound care solutions. Through its extensive sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.



In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology.



Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal(R) and Hydress(R) brands, as well as the sorbion sachet S(R) and sorbion sana(R) wound care products. It also has the right to develop and market the advanced wound care products Biovance(R) and Extracellular Matrix (ECM), as part of its agreement with Celgene Cellular Therapeutics. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.



For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.



Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.



Legal Notice Regarding Forward-Looking Statements



This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 24, 2014, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.


CONTACT: Alliqua, Inc.
Brian M. Posner, +1-215-702-8550
Chief Financial Officer
bposner@alliqua.com
or
Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider, +1-212-825-3210
cschneider@dgicomm.com
or
Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj, +1-212-825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com



Alliqua, Inc. logo


Page: 1


Related Keywords: BIOTECHNOLOGY, PHARMACEUTICALSPost/Production, Management, email, USA, Inc., Medicine, Disease, Surgery, Medication, Science, Communications Technology, Internet Technology, Medical, Biology, Email, Other,


DMO TEXT LINKS
(Click here to place a textlink on this site)

Get 10 days of free unlimited access to lynda.com.
What do you want to learn today? Online video tutorials to help you learn software, creative, and business skills.
Click Here!

HOT THREADS on DMN Forums
Content-type: text/html  Rss  Add to Google Reader or
Homepage    Add to My AOL  Add to Excite MIX  Subscribe in
NewsGator Online 
Real-Time - what users are saying - Right Now!

@ Copyright, 2014 Digital Media Online, All Rights Reserved